Trial Profile
A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-Ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; Veliparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2023 Planned End Date changed from 13 Apr 2024 to 30 Aug 2024.
- 15 Apr 2023 Planned End Date changed from 31 Aug 2023 to 13 Apr 2024.
- 01 Sep 2022 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.